Concepedia
Statistics
Publications
23
Citations
2K
H-Index
18
Active since
1994
Affiliations
Eli Lilly (United States)(Current)
The University of Texas MD Anderson Cancer Center
AstraZeneca (United States)
AstraZeneca (United Kingdom)
Washington University in St. Louis
Jan Cosaert is an author at Eli Lilly (United States) specializing in oncology, medicine, and pharmacology.
Publications per year
1994–2025
Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer
Eric Van Cutsem, Walter L. Vervenne, Jaafar Bennouna et al. · Journal of Clinical Oncology · 2009 · 643 citations · Full text
Medicine, Oncology, Pharmacology +12
Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial
William D. Tap, Robin L. Jones, Brian A. Van Tine et al. · The Lancet · 2016 · 588 citations
Medicine, Oncology, Pharmacology +9
An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer
Thomas Powles, Danielle Carroll, Simon Chowdhury et al. · Nature Medicine · 2021 · 116 citations
Medicine, Oncology, Pharmacotherapy +15
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial
Benjamin Besse, Elvire Pons‐Tostivint, Keunchil Park et al. · Nature Medicine · 2024 · 116 citations · Full text
Medicine, Oncology, Pharmacology +17
A phase 1 study of anti-TGFβ receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors
Anthony W. Tolcher, Jordan Berlin, Jan Cosaert et al. · Cancer Chemotherapy and Pharmacology · 2017 · 101 citations · Full text
Pharmacy, Immunology, Oncology +12
1–5 of 23